The March 2027 DUET-AD topline data is the primary catalyst; the $21M raise provides runway to that event but leaves no margin for delay. Monitor enrollment close of OLE-PD (Jan 29, 2027) and any early signals from CTAD presentations Nov 16-19.
Drug in focus
ANVS drug pipeline →buntanetap
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 Alzheimer's succeeds, NDA submission could come in early 2027 (symptomatic) or early 2028 (disease-modifying). Earliest potential FDA approval would be late 2028 at best.
- Next catalyst
- None dated
What to watchInvestors should watch for the Q1 2027 Alzheimer's Phase 3 symptomatic readout as the defining catalyst. The company will likely need additional financing before then given ~$14M cash and ~$17M/quarter burn. The Parkinson's miss on ITT primary endpoint is a cautionary precedent. Analyst consensus is strong-buy with $11 mean PT, but that reflects binary-option-like upside rather than de-risked fundamentals.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.9261entry
- T+1 · 21h ago −19.02%α −17.10% · $0.7500
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Annovis Bio reported a Q3 2026 net loss of $0.22 per share, narrower than the $0.37 loss in Q3 2025, but the company ended the quarter with only $2.8M cash, down from $19.5M at year-end 2025. The company raised $21M in a dilutive offering on Nov 6 to fund operations through the March 2027 DUET-AD Phase 3 data readout, which is the key catalyst.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $9.5M vs $7.3M in Q3 2025; basic EPS -$0.22 vs -$0.37
- Cash and equivalents $2.8M at Sept 30, 2026, down from $19.5M at Dec 31, 2025
- Raised $21M gross in Nov 6 offering; chairman contributed $5M
- DUET-AD Phase 3 trial fully enrolled (862 patients); 6-month data readout expected March 2027
- R&D expenses $15.8M in Q3 2026 vs $6.3M in Q3 2025, reflecting trial execution costs
- 42.7M shares outstanding at Sept 30, 2026, up from 27.2M at Dec 31, 2025
Financial Impact
Cash burn of ~$16.7M in Q3 2026; $21M offering extends runway to March 2027 data readout
Risk Factors
- Cash runway only extends to March 2027 data readout; any delay in results or need for additional trials would require further dilutive financing
- Massive share dilution (42.7M shares vs 27.2M at year-end 2025) and additional warrants outstanding
- NYSE delisting risk from prior non-compliance notice remains
- Phase 3 data readout is binary; failure would likely render equity worthless
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402540 |
Track record
19 reports on ANVS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.53% at T+20 after the May 20, 2026 report. 4 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 5/10 Viewing Entry $0.9261 Now $0.7500 −19.02% settles Feb 11
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago 424B5 Bearish 7/10 Entry $0.8449 Now $0.7500 +11.23% settles Feb 4
- Nov 5, 202611d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 6/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago Press Release Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Nov 4, 202612d ago 8-K Bearish 7/10 Entry $0.6689 Now $0.7500 −12.12% settles Feb 3
- Oct 30, 202617d ago 8-K Bearish 7/10 Entry $1.08 Now $0.7500 +30.56% settles Jan 29
- Oct 19, 202628d ago 8-K Neutral 1/10 Entry $0.9783 Now $0.7500 −23.34% settles Jan 15
- Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.05 Now $0.7500 −28.57% settles Jan 12
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers